GLP-1RA Use May Lower Overall Cancer Risk but Increase Kidney Cancer Risk in Obese Patients: JAMA

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-25 03:30 GMT | Update On 2025-08-25 05:13 GMT

USA: A new study published in JAMA Oncology has revealed that glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for type 2 diabetes management and weight loss, may have an impact on cancer risk among adults with obesity.

The research, led by Hao Dai and colleagues from the Department of Biostatistics and Health Data Science, Indiana University School of Medicine, explored the association between GLP-1RA use and the likelihood of developing cancer.

GLP-1RAs have become increasingly popular as anti-obesity medications, but their long-term safety profile, particularly to cancer, has remained unclear. To address this, the investigators conducted a retrospective cohort study using electronic health record data from OneFlorida+, a large multicenter health research network, covering the period from 2014 to 2024. The analysis followed a target trial emulation approach to ensure robust comparisons between users and nonusers of GLP-1RAs.

The study population included 86,632 adults aged 18 years and older, all eligible for anti-obesity medications and free from prior cancer diagnoses. Participants were matched in a 1:1 ratio using propensity scores, resulting in two groups: 43,317 individuals who used GLP-1RAs and 43,315 who did not. The average age of participants was 52.4 years, and women constituted 68.2% of the sample.

Researchers evaluated the incidence of 14 cancers, including 13 obesity-related types—such as liver, pancreatic, colorectal, breast, and endometrial cancers—along with lung cancer.

The key findings of the study were as follows:

The overall cancer incidence rate was 13.6 per 1,000 person-years among GLP-1RA users compared to 16.4 per 1,000 person-years in nonusers.
This difference reflected a significantly lower overall cancer risk for GLP-1RA users, with a hazard ratio (HR) of 0.83.
GLP-1RA use was associated with a reduced risk of endometrial cancer, with an HR of 0.75.
The risk of ovarian cancer was also lower among GLP-1RA users, with an HR of 0.53.
Meningioma risk showed a decrease as well, with an HR of 0.69 in individuals taking GLP-1RAs.
A marginal, nonsignificant increase in kidney cancer risk was noted among GLP-1RA users, with an HR of 1.38.

The authors concluded that while GLP-1RA therapy appears to lower the overall risk of cancer in individuals with obesity, the possibly elevated risk for kidney cancer warrants attention. They emphasized the importance of long-term follow-up studies to better understand these associations and uncover the underlying biological mechanisms.

These findings add an important dimension to the discussion around GLP-1RA use, suggesting potential protective effects against several cancers while highlighting the need for ongoing safety evaluations as these drugs continue to be widely prescribed.

Reference:

Dai H, Li Y, Lee YA, et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncol. Published online August 21, 2025. doi:10.1001/jamaoncol.2025.2681

Article Source : JAMA Oncology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

GLP-1RA Use May Lower Overall Cancer Risk but Increase Kidney Cancer Risk in Obese Patients: JAMA

Similar News

Poor dental health closely associated with the risk of gastric cancer: Study

Intermittent Fasting Under 8 Hours May Raise Heart Death Risk by 135 Percent: Study Finds

New cancer drug boosts effectiveness of chemotherapy-even in resistant tumours: Study

Merck's SpringWorks Therapeutics gets nod for Ogsiveo from European Commission for adults with Desmoid Tumors

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients: Study

Heart-healthy habits also prevent cancer, Alzheimer's, COPD, other diseases, Emory study finds

Real-World Case: Managing Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Akhil Kapoor